High glycolytic activity in tumor cells leads to tumor cell-mediated glucose restriction, dampens the ability of T cells to produce IFN-γ, suppresses anti-tumor effector functions of Th1CD4+ T cells by limiting the Ca2+-NFAT signaling pathway (15, 16). This evidence concerns the gene IFNG and neoplasm.